Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
QLGN
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.22
N/A
-55.00
vs -90.00
Q3.22
N/A
-50.00
vs -50.00
Q4.22
N/A
-2.02
vs -75.00
Q1.23
N/A
-39.00
vs -70.00
Q2.23
N/A
-34.50
vs -55.00
Q3.23
N/A
-32.00
vs -50.00
Q4.23
N/A
-0.47
vs -2.02
Q1.24
N/A
-0.47
vs -39.00
Q2.24
N/A
-17.50
vs -34.50
Q3.24
N/A
-4.70
vs -32.00
Sales Growth
YoY
Current
Estimates
Q2.22
+28%
1.4M vs 1.1M
Q3.22
+25%
1.4M vs 1.2M
Q4.22
-6%
1.4M vs 1.5M
Q1.23
+123%
1.6M vs 722K
Q2.23
+14%
1.6M vs 1.4M
Q3.23
+451%
7.9M vs 1.4M
Q4.23
-100%
NA vs 1.4M
Q1.24
-100%
NA vs 1.6M
Q2.24
-100%
NA vs 1.6M
Q3.24
-100%
NA vs 7.9M
Return on Equity
QoQ
Q4.22
-118%
-1.18
vs -0.31
Q1.23
-84%
-0.84
vs -1.18
Q2.23
-170%
-1.70
vs -0.84
Q3.23
+223%
2.23
vs -1.70
Q4.23
+117%
1.17
vs 2.23
Q1.24
+58%
0.58
vs 1.17
Q2.24
+37%
0.37
vs 0.58
Q3.24
+84%
0.84
vs 0.37
Institutionnal Ownership
QoQ
Q4.20
27
27
vs 15
80%
Q1.21
32
32
vs 27
19%
Q2.21
30
30
vs 32
-6%
Q3.21
28
28
vs 30
-7%
Q4.21
29
29
vs 28
4%
Q1.22
31
31
vs 29
7%
Q2.22
25
25
vs 31
-19%
Q3.22
24
24
vs 25
-4%
globenewswire.com
9 hours ago
globenewswire.com
9 hours ago
globenewswire.com
17 hours ago
Relative Strength
QLGN
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
NASDAQ
Unprofitable
Unprofitable
0.12 ( 3.48%)
Relative Strenght
12
Volume Buzz
-87%
Earning Acce
No
Dist 52w H.
88%Forecast
NaN%2025-Revenue
-644%2025-EPS
-278%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
